Question explored with the scientific record
How effective is Shingrix after the second shot?
After two doses, Shingrix cuts shingles risk by about 85% in real-world use, but the protection wanes over years and the safety data has gaps.
The best evidence comes from the manufacturer-funded ZOE trials. In adults 50 and older, two doses showed 97.2% efficacy against shingles at a mean of 3.2 years follow-up [1]. Long-term follow-up of the same trial participants found efficacy dropping from 97.7% in year one to 84.1% by year eight after the second shot [1]. A separate review reports similar waning: 97.6% at year one, 92.0% at year two, 84.7% at year three [2].
Real-world numbers are lower. A large Medicare study of people 65 and older found two-dose effectiveness of 70.1%, compared to 56.9% after just one dose [1]. A Kaiser Permanente study of adults with inflammatory bowel disease found about 65% effectiveness after two doses [6]. The gap between trial and real-world results is common when a manufacturer runs the studies.
On safety, the picture is mixed. The trials report mostly mild-to-moderate injection-site reactions lasting 1-3 days [4]. But a VAERS-based analysis found a positive safety signal for autoimmune disease flares, especially in people with lupus (reporting odds ratio 7.5) [5]. Most flares happened within three days of vaccination [5]. A separate analysis found about 3 excess cases of Guillain-Barré syndrome per million doses in people 65 and older [1]. The Italian real-world study of high-risk patients found 16 disease flares among 675 people, and 26 cases of shingles after vaccination in 787 people followed [7].
| Population | Two-dose effectiveness | Source |
|---|---|---|
| Trial participants 50+ | 97.2% at 3.2 years | ZOE-50 trial [1] |
| Trial participants 70+ | 89.8% | ZOE-70 trial [3] |
| Medicare 65+ (real-world) | 70.1% | Izurieta et al. [1] |
| IBD patients 50+ (real-world) | 65.1% | Kaiser study [6] |
My call: Shingrix after two doses provides meaningful but incomplete protection that wanes over time, with real-world effectiveness around 65-70% in older adults. The safety data is largely from manufacturer-funded trials; independent long-term safety studies are thin. Confidence: moderate.
Sources used 7
-
Prevention of Herpes Zoster: A Focus on the Effectiveness and Safety of Herpes Zoster Vaccines
This narrative review finds real-world vaccine effectiveness of about 46% for live zoster vaccine and about 85% for recombinant zoster vaccine, with mostly local reactions and a small Guillain-Barré syndrome signal to monitor.
DOI: 10.3390/v14122667 -
Understanding the immunology of Shingrix, a recombinant glycoprotein E adjuvanted herpes zoster vaccine
A comprehensive review detailing how the Shingrix recombinant gE herpes zoster vaccine, with the AS01_B adjuvant, elicits robust humoral and polyfunctional CD4+ T cell responses, achieving high and durable protection against herpes zoster across older adults and various immunoco…
DOI: 10.1016/j.coi.2019.02.009 -
What is Different about Recombinant Herpes Zoster Vaccine?
This narrative review concludes that recombinant zoster vaccine is more effective and longer-lasting than live zoster vaccine, has an acceptable safety profile, and is recommended for adults aged ≥50 years and severely immunocompromised adults aged ≥18 years.
DOI: 10.3904/kjm.2024.99.4.180 -
Healthy ageing: Herpes zoster infection and the role of zoster vaccination
This narrative review concludes that adjuvanted recombinant zoster vaccine prevents herpes zoster and postherpetic neuralgia, has a reassuring safety profile, and is a key action for healthy ageing.
DOI: 10.1038/s41541-023-00757-0 -
Risk of autoimmune disease flares after recombinant zoster vaccine: A vaccine safety analysis based on the Vaccine Adverse Event Reporting System database
This VAERS-based study quantified the risk of autoimmune-disease flares after recombinant zoster vaccination across five diseases (RA, MS, IBD, psoriasis, SLE), finding a positive safety signal with higher risk in SLE and most flares occurring within 3 days, highlighting the nee…
DOI: 10.1080/21645515.2025.2590257 -
Effectiveness and safety of the recombinant zoster vaccine in adults aged ≥50 years with inflammatory bowel disease
In a real-world Kaiser Permanente Southern California cohort of adults aged ≥50 with inflammatory bowel disease (IBD), two doses of recombinant zoster vaccine (RZV) significantly reduced herpes zoster incidence by about 65% without increasing short-term IBD flare risk, supportin…
DOI: 10.1080/21645515.2025.2576981 -
Safety profile and medium- to long-term protection of the Recombinant Zoster Vaccine (RZV) in a cohort of high-risk patients: real-world data from a General Hospital in Southern Italy, 2021–2025
A prospective real-world study in a Southern Italian hospital evaluated the safety, disease-flare potential, and medium-to-long-term protection against herpes zoster after Recombinant Zoster Vaccine (RZV) in a medically diverse, vulnerable adult population, finding acceptable sa…
DOI: 10.1080/14760584.2025.2589216